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Departamento de Biologia Celular, Universidade de Brası´lia DF, BrasilABSTRACT Several voltage-gated ion channels are modulated by clinically relevant doses of general anesthetics. However,
the structural basis of this modulation is not well understood. Previous work suggested that n-alcohols and inhaled anesthetics
stabilize the closed state of the Shaw2 voltage-gated (Kv) channel (K-Shaw2) by directly interacting with a discrete channel site.
We hypothesize that the inhibition of K-Shaw2 channels by general anesthetics is governed by interactions between binding and
effector sites involving components of the channel’s activation gate. To investigate this hypothesis, we applied Ala/Val scanning
mutagenesis to the S4-S5 linker and the post-PVP S6 segment, and conducted electrophysiological analysis to evaluate the
energetic impact of the mutations on the inhibition of the K-Shaw2 channel by 1-butanol and halothane. These analyses iden-
tified residues that determine an apparent binding cooperativity and residue pairs that act in concert to modulate gating upon
anesthetic binding. In some instances, due to their critical location, key residues also influence channel gating. Complementing
these results, molecular dynamics simulations and in silico docking experiments helped us visualize possible anesthetic sites
and interactions. We conclude that the inhibition of K-Shaw2 by general anesthetics results from allosteric interactions between
distinct but contiguous binding and effector sites involving inter- and intrasubunit interfaces.INTRODUCTIONDiscoveries made over the past two decades support the
notion that proteins contain relatively specific general anes-
thetic sites, with ion channels perhaps being the most phys-
iologically relevant (1–5). Ligand-gated, voltage-gated, and
nongated ion channels are among the best-known targets.
Thus, it is hypothesized that direct modulation of diverse
ion channels by general anesthetics may explain distinct
physiological end points of anesthesia and common side
effects of general anesthetics (2,3). Although this hypothesis
has gained recognition in recent years, and crystallographic
studies are confirming the presence of discrete general
anesthetic sites in ion channels (6), several fundamental
questions remain unanswered. What common structural
features of protein cavities permit the interaction of general
anesthetics with diverse and structurally distinct ion chan-
nels? What are the structural bases of the link between
cavity occupancy and functional modulation by anesthetics?
Answering these questions is a key step toward under-
standing the molecular mechanisms of general anesthesia
and designing anesthetics with fewer side effects and higher
therapeutic indices.
We previously demonstrated that the voltage-gated Kþ
(Kv) channel Shaw2 (K-Shaw2) is rapidly and reversibly in-
hibited by clinically relevant anesthetic doses of short- and
medium-chain n-alcohols (C2-C6) and inhaled anesthetics
(halothane and isoflurane) (7–11). In particular, we showed
that halothane and 1-butanol (1-BuOH) share a putativeSubmitted May 31, 2011, and accepted for publication August 15, 2011.
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0006-3495/11/10/1613/10 $2.00binding site in the channel (7), and that n-alcohols stabilize
the closed state(s) (9). Related studies have also shown that
the S4-S5 linker is sufficient and necessary to confer modu-
lation by n-alcohols and general anesthetics, and that the
a-helicity of this linker is critical for the modulatory action
(7,9,12–14). Moreover, the second proline in the PVP
motif of the S6 segment (P410) is also unique because the
mutation P410A switches the modulatory response from
inhibition to potentiation (12,15). These studies led to the
notion of an amphiphilic anesthetic cavity involving two
key components of the activation machinery of Kv channels:
the S4-S5 linker and the distal part of the S6 segment. Inter-
actions between these regions are the basis of the electrome-
chanical coupling underlying voltage-dependent gating of
voltage-gated ion channels (16–18). Although these studies
generally support the contributions of the K-Shaw2 activa-
tion gate to general anesthetic action, systematic molecular
mapping is necessary to locate the sites of action. We
hypothesize that the inhibition of K-Shaw2 channels by
n-alcohols and inhaled anesthetics is governed by the allo-
steric cross talk between binding and effector sites at the
channel’s activation gate. These sites may overlap or exhibit
distinct locations.
To test this hypothesis, we investigated the actions of
1-BuOH and halothane by combining systematic Ala/Val
scanning mutagenesis (Fig. 1), electrophysiological evalua-
tion of dose-response relations, and molecular modeling.
These experiments revealed that the apparent binding coop-
erativity depends on critical interacting residues in the S4-
S5 linker and the post-PVP S6 segment (Fig. 1), which in
some instances also influence the energetics of anestheticdoi: 10.1016/j.bpj.2011.08.026
FIGURE 1 Topology and structure of the S4-S5 linker and S6 segment
in the K-Shaw2 channel, with the Ala/Val scan region highlighted in gray
in B and C. (A) Sequences of the S4-S5 linker and S6 segment (mutated
residues shown in bold). A lowercase ‘‘n’’ above the sequence indicates
nonexpressing mutants; numbers indicate the number of the final residue
in each segment. (B) K-Shaw2 exhibits classical Kv channel membrane
topology with six TM segments and intracellular termini. The first four
membrane-spanning segments form the voltage sensor, and the last two
segments form the pore domain. (C) Structural model of the S4-S5 linker
and the S6 segment of K-Shaw2. The inset depicts a tetrameric model of
the K-Shaw2 pore domain, including the S4-S5 linkers. This homology
model was created by MD simulation (Supporting Material).
FIGURE 2 Dose-inhibition analysis of the wild-type K-Shaw2 channel
1614 Barber et al.action and voltage-dependent gating. Additional observa-
tions demonstrated significant nonadditive energetic inter-
actions between residue pairs possibly acting as anesthetic
effector sites. Complementing these results, molecular
dynamics (MD) simulations and in silico docking experi-
ments yielded a plausible atomistic map displaying distinct
but contiguous binding and effector sites formed by the
moving parts of the channel’s activation gate. This study
sets the stage to investigate the molecular mechanisms
underlying the relevant modulation of voltage-
gated Naþ, Caþ, and nonselective cation channels by
general anesthetics (19–25).and representative Ala/Val mutants. (A) Normalized current versus time
plot of wild-type K-Shaw2. Upon application of increasingly higher doses
of 1-BuOH (mM), there is an incremental inhibition of the current. This
inhibition reaches equilibrium and is reversible upon washout. The inset
shows the whole-oocyte K-Shaw2 currents corresponding to the experiment
shown in the main panel evoked by a step from 100 to þ60 mV; scale for
inset indicates 4 mA (y axis) and 100 ms (x axis). All mutants were sub-MATERIALS AND METHODS
Experimental details about the Ala/Val scanning mutagenesis, heterologous
expression, electrophysiology, MD simulations, and in silico docking are
described in the Supporting Material, which includes a summary of defini-
tions (Table S1).
jected to this experimental strategy. (B) Semilogarithmic plots of normal-
ized current versus anesthetic concentration for wild-type K-Shaw2. The
solid lines depict the best Hill equation fits, which yielded the following
parameters for halothane: K0.5 ¼ 0.26 mM, nH ¼ 1.2; and the following
best-fit parameters for 1-BuOH: K0.5 ¼ 11.2 mM, nH ¼ 1.6. (C) The effects
of Ala/Val mutations on the 1-BuOH dose-inhibition relation. A417V
shifted the relation to the right (K0.5 ¼ 39.4 mM, nH ¼ 1.7) and the double
mutation A326V/Y419A caused an even larger shift and increased the
apparent cooperativity (K0.5 ¼ 57.7 mM, nH ¼ 3.4). (D) The effects of
Ala/Val mutations on the halothane dose-inhibition relation. A417V
showed a rightward shift (K0.5 ¼ 0.88, nH ¼ 1.7), and the double mutation
A326V/Y419A exhibited an even larger shift (K0.5¼ 1.34, nH ¼ 2.5). In all
cases (B–D), the points represent the average of 4–45 independent determi-
nations.RESULTS
Anesthetic dose-inhibition relations
of wild-type and mutant K-Shaw2
To map the contributions of individual residue side chains
to putative anesthetic binding and effector sites in K-Shaw2
and the resulting inhibition, we applied Ala/Val scanning
mutagenesis to the S4-S5 linker and the post-PVP S6
segment, and functional characterization in Xenopus oocytes
under two-electrode voltage-clamp conditions (SupportingBiophysical Journal 101(7) 1613–1622Material). These regions were chosen because 1), they play
central roles in Kv channel gating, and general anesthetics
influenceK-Shaw2 gating; and 2), previous work has demon-
strated the importance of these regions in the modulation of
K-Shaw2 by general anesthetics. As shown previously,
both n-alcohols (e.g., 1-BuOH) and halothane inhibit wild-
type K-Shaw2 currents in a reversible and dose-dependent
manner (Fig. 2, A and B). Assuming that the Hill equation
describes the average dose-response curves (Supporting
Material), we obtained best-fit parameters of K0.5 ¼
11.2 mM and nH ¼ 1.6 for 1-BuOH, and K0.5 ¼ 0.26 mM
and nH¼ 1.2 for halothane (Fig. 2 B, Table S2, and Support-
ing Material). These values are comparable to those previ-
ously reported and indicate that K-Shaw2 is sensitive to
clinically relevant doses of halothane (minimum alveolar
concentration¼ 0.25 mM). Because 1-BuOH is significantly
less volatile than halothane, and these drugs share a putative
binding site in K-Shaw2 (7), we first used 1-BuOH as a
tool to probe the inhibition of all mutants (Table S2). This
Anesthetic Sites in a Kþ Channel 1615initial screening allowed us to select mutants for subsequent
investigation with halothane. Several single S4-S5 linker
mutations had modest but significant effects on the K0.5;
Q320A, T321V, F322A, and L329A increased it, whereas
S325A and A326V decreased it. By contrast, most mutations
in the post-PVP S6 segment (A417V, M418A, Y419A,
and Y420A) increased the K0.5 to a greater extent (e.g.,
Fig. 2 C). Several mutations had a relatively modest impact
on the nH, which typically remained between 1.4 and 2.
However, a few yielded larger changes. The nH-values of
T321V, E328A, and L329A in the S4-S5 linker, and
Y420A in S6 are reduced (1.2, 1.2, 1.2, and 1.1, respectively),
whereas the nH-values of K316A, S414A, and M418A are
increased (2.1, 2.1, and 2.2, respectively). Relative to single
mutations, the impact of double mutations on K0.5 and nH
is generally larger. Although one double mutation within
the S4-S5 linker (Q320A/A326V) affected the 1-BuOH
response significantly, even larger changes were caused by
paired mutations across the putative interface between the
S4-S5 linker and the post-PVP S6 segment (e.g., Fig. 2 C
and Table S2). The K0.5-values for Q320A/A326V, Q320A/
A417V, Q320/M418A, Q320A/Y420A, A326V/A417V,
and A326V/Y419A are 32, 47, 22, 48, 94, and 58 mM,
respectively. The nH-values for A326V/A417V and A326V/
Y419A are 4.5 and 3.4, respectively, and thus are the largest
of the entire scan. Nevertheless, across the entire scan,
there is no significant correlation between K0.5 and nH
(Fig. S1 B).
We next examined the properties of the halothane dose-
response curve for a group of selected single and double
mutants with significantly altered responses to 1-BuOH
(Fig. 2 D and Table S3). The K0.5-values of Q320A,
A326V, A417V, and Y420A are clearly increased (0.5,
1.2, 0.9, and and 1 mM, respectively), and the nH-values
are modestly changed for Q320A, S325A, A326V, A417V,and Y419A (1.6, 1, 1.6, 1.6, and 1, respectively). Three
double mutations have a more profound impact on the
K0.5 of halothane: Q320A/A326V, Q320A/Y420A, and
A326V/A417V yielded 1.8, 1.4, and>>4 mM, respectively.
Essentially, A326V/A417V is insensitive to halothane, and
whereas the nH for Q320A/A326V is 2.8, that of A326V/
A417V is 1.8. As for 1-BuOH, there was no significant
correlation between the K0.5- and nH-values of halothane
(Fig. S1 B). Nevertheless, consistent with the presence of
overlapping sites for 1-BuOH and halothane in K-Shaw2,
the overall impact of the mutations on the K0.5 for these
anesthetics is similar (e.g., compare Fig. 2, C and D), hence
there is a significant correlation between the K0.5-values of
1-BuOH and halothane (Fig. S1). These results add new
support to the notion of a general anesthetic action involving
the interface between the S4-S5 linker and the post-PVP S6
segment of K-Shaw2.Energetic impact of mutations on the modulation
of K-Shaw2 by general anesthetics
To evaluate the energetic impact of all mutations on the
modulation of K-Shaw2 by the anesthetics, we used the
parameters derived from the analysis of dose-response
curves to calculate the apparent free-energy change (DG ¼
nHRTlnK0.5; Supporting Material). The Hill coefficient
(nH), which is >1 in the wild-type and changes significantly
in several mutants (Table S2 and Table S3), scales the
free-energy change. Then, we defined DDG ¼ DGMUT –
DGWT. For 1-BuOH, the absolute impact of 12/15 single
S4-S5 linker mutations is relatively small or modest
(%1 kcal/mol; Fig. 3 A and Table S2). However, the DDG
of the remaining three mutants (E328A, L329A, and
T321V) is significantly larger and unfavorable (þ1.4, þ1.5,
and þ1.5 kcal/mol, respectively). The energetic impact ofFIGURE 3 Energetic impact of Ala/Val muta-
tions on the modulation of K-Shaw2 by 1-BuOH.
(A) Apparent free-energy changes induced by
single S4-S5 and S6 mutations. These changes
are calculated relative to the wild-type apparent
free-energy change as indicated in the main
text. (B) Absolute coupling energies for double
K-Shaw2 mutants; note that A326V appears on
both axes due to intra-S4-S5 mutations. DMCA
was used to calculate these energies as described
in Table S1. Dark gray bars depict coupling
energies > 2 kcal/mol. (C) Scatter plot of DDG
versus nH. The line is the best-fit linear regression
(R2¼ 0.75). Two outliers with high nH-values were
excluded from the regression analysis. These
mutants exhibit very low 1-BuOH sensitivities,
and very high doses were not investigated, which
limited the estimation of the Hill equation para-
meters (Table S1).
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is >1 kcal/mol (þ1.2 and þ2.1 kcal/mol for A417V and
Y420A, respectively). In addition, single and double muta-
tions that change the nH have the most significant energetic
impact. To further examine this interaction, we plotted the
DDG of all single and double mutants against the nH and
found a significant correlation (Fig. 3 C). In contrast, DDG
and K0.5 are not correlated (Fig. S1 C). We then examined
selected double mutants, including the S4-S5 linker and
S6 mutations, that significantly affected nH and/or K0.5
(e.g., Q320A, T321V, S325A, A326V, T330V, M418A,
A417V, Y419A and Y420A; Table S2), and applied double-
mutant cycle analysis (DMCA) to investigate the additivity
of the energetic impacts of the mutations (Fig. 3 B; Table
S2). This approach can help identify putative anesthetic
effector sites. In this context, effector sites are residues
that directly or allosterically interact with each other to
control how the anesthetic perturbs gating upon interaction
with a binding site. The coupling energies of 7/13 double
mutants (Q320A/T321V, Q320A/M418A, S325A/A326V,
S325A/A417V, A326V/A417V, A326V/Y419A, and A326V/
Y420A) are substantial (3.5, 1, 2.1, 1.5, 2, 2.9,
and 4 kcal/mol, respectively).
Overall, the thermodynamic analysis indicates that
specific residues in the S4-S5 linker and the post-PVP S6
segment may play significant structural roles in determining
the action of general anesthetics on K-Shaw2. Furthermore,
the DMCA results suggest that direct or indirect interactions
between residue pairs (Q320A/T321V, S325A/A326V,
A326V/A417V, A326V/Y419A, and A326V/Y420A) are
especially critical, and the energetic impact of the mutations
on anesthetic action is closely tied to changes in the
apparent cooperativity (nH) of anesthetic action. To visu-
alize the key residues on the channel structure, we createdBiophysical Journal 101(7) 1613–1622an atomic membrane equilibrated MD model of K-Shaw2
(Supporting Material) and mapped the energetic effects
(DDG) of the mutations (Fig. S2). This map reveals distinct
interfacial patches involving relatively high-impact residues
in the S4-S5 linker and the post-PVP S6 segment.
Based on the effects of mutations on the Hill equation
parameters for 1-BuOH, we also investigated the energetic
impact of selected single and double mutations on the
interaction between halothane and K-Shaw2 (Fig. 4 A;
Table S3). Despite some significant changes in the Hill
equation parameters, the DDG values of individual S4-S5
linker and S6 mutants (e.g., Q320A, S325A, A326V,
A417V, M418A, Y419A, and Y420A) are relatively small
(1.2, þ1.1, 0.5, 0.9, 1.1, þ1.2, and 0.1 kcal/mol).
Nevertheless, the coupling energies of 5/6 double mutants
tested with halothane and subjected to DMCA are substan-
tial (Fig. 4 B). Q320A/A326V, S325A/A326V, S325A/
A417V, and A326V/Y419A yield 2.8, 2.6, 2.8, and
4.3 kcal/mol, respectively, and A326V/A417V, which virtu-
ally eliminates the inhibition by halothane, has an even
larger coupling energy ([4 kcal/mol). Moreover, as found
for 1-BuOH,DDG and nH are highly correlated (Fig. 4 C). In
general, the results obtained with halothane corroborate the
significance of residues in the S4-S5 linker and the post-
PVP S6 segment as important players in the interaction of
K-Shaw2 with general anesthetics.Interplay between voltage-dependent gating
and general anesthetic action
The S4-S5 linker and the post-PVP S6 segment play critical
roles in the electrochemical coupling that underlies voltage-
dependent gating (16–18). To assess whether the effects of
mutations on the inhibition by 1-BuOH and halothane areFIGURE 4 Energetic impact of Ala/Val muta-
tions on the modulation of K-Shaw2 by halothane.
(A) Apparent free-energy changes induced by
single S4-S5 and S6 mutations (see legend to
Fig. 3 for additional information). (B) Absolute
coupling energies for double K-Shaw2 mutants
(see legend to Fig. 3). The þ sign above the tallest
bar indicates that the coupling energy is estimated
to be [5 kcal/mol. (C) Scatter plot of DDG
versus nH. The line is the best-fit linear regression
(R2 ¼ 0.87).
Anesthetic Sites in a Kþ Channel 1617byproducts of possible gating effects, we measured the shift
in activation voltage (DV), time to 50% activation (T0.5), and
degree of inactivation at the end of a 400-ms pulse
to þ70 mV (I400/Ipeak; Supporting Material and Table S4).
If anesthetics preferentially interact with resting/closed
K-Shaw2 channels, the energetics of anesthetic action would
be proportional to the relative stability of the closed confor-
mation(s). Accordingly, some mutants (E328A, L329A,
A417V, Q320A/A326V, and Q320A/A417V) exhibit rela-
tively large leftward shifts (>5 mV) in voltage-dependent
activation (i.e., a relative destabilization of closed states)
and corresponding positiveDDG values (>1 kcal/mol) calcu-
lated from experiments at a fixed voltage that most likely
does not saturate the open probability (Supporting Material
and Table S4).
These results suggest that any other mutation(s) whose
main effect would be to shift voltage-dependent gating
might also secondarily affect anesthetic action in other Kv
channels, and the inhibition by the anesthetics might exhibit
state dependence. To test these premises, we exploited the
triple ILT mutation (V369I, I372L, and S376T) in the
voltage sensor of ShakerB channels, which confers a depo-
larized K-Shaw2-like activation phenotype (26). Relative
to the wild-type counterpart, the activation curve of the
ShakerB-ILT mutant exhibits a dramatic rightward shift
of þ123 mV, demonstrating a strong relative stabilization
of the channel’s closed state(s) (Fig. S3 A). Despite this
large change, the ShakerB-ILT mutant is resistant to
1-BuOH (K0.5 ¼ 47 mM, nH ¼ 1.4; Fig. S3 C) when tested
at a strongly depolarized voltage (þ100 mV) corresponding
to ~50% activation. Testing it at less depolarized voltages
(þ70 to þ80) modestly increases the inhibition to a
maximum of ~70% at 50 mM 1-BuOH (Fig. S3 B). Interest-ingly, ShakerB wild-type yields similar anesthetic resistance
(K0.5 ¼ 57 mM, nH ¼ 1.5; Fig. S3 C) and state-dependent
inhibition despite its normal voltage dependence (Fig. S4
A). Thus, the inhibition is maximal at voltages where chan-
nels may populate closed-activated states, and becomes
weaker as the open state becomes progressively more
represented. Nevertheless, the maximal inhibition of mutant
and wild-type ShakerB channels does not match that of
K-Shaw2, which is also state-dependent but nearly complete
(96%) at 50 mM 1-BuOH and over a voltage range where
the inhibition increases to a maximum and levels off
(Fig. 2 and Fig. S4 C).
In the light of these results, we made two additional
predictions: First, the converse triple VIS mutation
(I302V, L304I, and T308S) in K-Shaw2 (K-Shaw2-VIS)
may exhibit left-shifted voltage-dependent activation and a
concomitant decrease in the apparent anesthetic affinity.
Accordingly, voltage-dependent activation of the K-Shaw2-
VIS mutant is somewhat leftward shifted (DV ¼ 20 mV)
and is slightly less sensitive to 1-BuOH than the wild-
type counterpart (K0.5 ¼ 19 mM, nH ¼ 1.5; Fig. S3 C).
Second, the nongated K-Shaw2 P410D mutant may become
insensitive to general anesthetics. This mutation targets
the second P in the PVP motif, rendering K-Shaw2
constitutively open (27). Thus, the current-voltage relation
of K-Shaw2 P410D is approximately linear and displays
a reversal potential consistent with a conductance highly
selective for Kþ (Fig. 5, A and B). Moreover, as an extreme
example of state-dependent inhibition, the P410D mutant
is highly resistant to general anesthetics (Fig. 5 C). Relative
to wild-type K-Shaw2, P410D is 22 times less sensitive to
1-BuOH (K0.5 ¼ 250 mM) and 23 times less sensitive to
halothane (K0.5 ¼ 6.1 mM). This result also confirmsFIGURE 5 General anesthetic action on the
constitutively open K-Shaw2 P410D mutant
channel. (A) P410D currents evoked from a holding
voltage of100 mV by voltage steps ranging from
150 to 0mV at 10-mV intervals. (B) Comparison
of normalized current-voltage relations from
wild-type and the P410D mutant. The current of
the constitutively open P410D mutant reverses
polarity at 98 mV, as expected for a Kþ-selective
Kv channel. (C) Comparison of the 1-BuOH and
halothane dose-inhibition plots from wild-type
and the P410D mutant. For the P410D mutant,
the dashed and solid gray lines are the best Hill
equation fits with the following parameters for
1-BuOH: K0.5 ¼ 250 mM, nH ¼ 1.2; and the
following best-fit parameters for halothane:
K0.5 ¼ 6.1 mM, nH ¼ 1.9. Wild-type data are
replotted from Fig. 2.
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icantly affect the properties of the open state at the unitary
level (9).
Although the examples described above clearly link
voltage-dependent gating to the modulation of K-Shaw2
by general anesthetics, there is no systematic general corre-
lation between the energetic impact of all Ala/Val mutations
and the gating properties of the K-Shaw2 channel (Fig. S1
and Table S4). Only in a few of the cases mentioned above
(~15% of mutants) did this correlation become apparent. In
a larger number of cases (45%), activation gating changes
are not associated with significant changes in the energetic
impact of the mutations, and in some others the effects are
inversely related (T321V, Q320A/Y420A, A326V/A417V,
and A326V/Y419A). Thus, mutations that affect gating
may also affect anesthetic action because the inhibition is
gating-state-dependent; however, the lack of a general rela-
tionship suggests that many mutations in the investigated
regions primarily influence binding and/or effector sites of
general anesthetics in K-Shaw2.Modeling the K-Shaw2 structures in the open
and closed states
To investigate putative general anesthetic binding sites at the
atomic level, we first created full-atomistic structural
models for the transmembrane domain (TM) of K-Shaw2
by means of comparative protein modeling (28). Models
of the resting-closed and activated-open states of K-Shaw2
were based on previously reported modeling of the homol-
ogous ShakerB-like Kv1.2 channel (Supporting Material).
The K-Shaw2 models were equilibrated in a fully hydrated
phospholipid membrane by an ~18 ns MD simulation. In
each of the channel subunits in the tetrameric channel, the
TM remained stable in its starting resting-closed or acti-
vated-open conformations throughout the simulations
(Fig. S5). In the MD run, the root mean-square deviation
values for the whole TM domain, as well as for segments
S1–S6 and the S4-S5 linker, range from 1.0 to 3.0 A˚
(Fig. S6), which agrees with the structural drift quantified
in previous simulation studies of KcsA (29) and other Kþ
channels (30,31). The good stereochemical quality of the
relaxed K-Shaw2 structures was confirmed by further Pro-
check analyses (32).In silico docking of 1-BuOH and halothane
onto K-Shaw2
Whereas the resting closed state of K-Shaw2 is preferen-
tially sensitive to general anesthetics (see above), Kv1.2 is
resistant. High anesthetic doses (50 mM 1-BuOH or
2 mM halothane) inhibit this channel by %20% (data not
shown). We exploited these differences to identify likely
general anesthetic cavities in membrane-equilibrated atom-
istic models of K-Shaw2 (closed and open) and Kv1.2Biophysical Journal 101(7) 1613–1622(closed). We subjected each isoform and conformation to
in silico docking by probing the binding of both 1-BuOH
and halothane to 10 equilibrium structures to account for
the influence of molecular flexibility on ligand binding
(Supporting Material). Then, we used a subtraction method
to resolve unique 1-BuOH and halothane docking sites on
the K-Shaw2 closed structure (Supporting Material). To
carry out this strategy, we first estimated the effective
molecular binding constant (Bi) of the ligand for a given
binding site i on the receptor structures. We computed Bi
as the ligand energy-weighted binding probability by
considering the entire space of docking solutions. We then
compared the affinity of the ligand for a given site on the
K-Shaw2 closed conformation with that of the K-Shaw2
open conformation and the Kv1.2 closed conformation by
quantifying the difference between the effective molecular
binding constants:
DBi ¼ BiðShawclosedÞ  BiðjÞ for
j ¼ Shawopen;Kv1:2closed

:
The in silico docking analyses revealed that 1-BuOH
binds to K-Shaw2 (closed and open) and Kv1.2 (closed) at
multiple sites with a diverse range of binding affinities
(Fig. S7). Specifically, 1-BuOH binds to eight distinct loca-
tions on the K-Shaw2 closed structure (hereafter called sites
1–8). The calculation also shows that 1-BuOH binds to the
K-Shaw2 open conformation through all of these sites
except site 3. Despite a similar pattern for the interaction
with the channel in both conformations, 1-BuOH interacts
with the closed K-Shaw2 conformation with enhanced affin-
ities in sites 3, 4, 6, and 8. Compared with the Kv1.2 closed
structure, sites 3, 6, and 8 in the closed K-Shaw2 channel
also exhibit higher affinity. Further docking calculations
demonstrate that halothane binding sites on the K-Shaw2
closed structure overlap with all sites determined for
1-BuOH but site 6 (Fig. 6). The subtraction analysis identi-
fied sites 2, 3, and 5 as possible halothane interaction spots
in the closed K-Shaw2 conformation. Compared with
K-Shaw2 (open) and Kv1.2 (closed), these sites display
enhanced affinities.
Although they are structurally heterogeneous, the identi-
fied sites are cavities located at the interfacial region
between helical segments of the channel, i.e., the S4-S5
linker, S5, and S6. For a cutoff distance of%4.6 A˚, Table 1
highlights the amino acid side chains of K-Shaw2 that
may interact with the anesthetics at these sites. Sites 3, 5,
and 8 are delineated by hydrophobic amino acids, whereas
sites 2 and 6 are predominantly hydrophilic. Overall,
whereas K-Shaw2 inhibition by 1-BuOH implicates sites
3, 6, and 8, the inhibition of the channel by halothane impli-
cates sites 2, 3, and 5. Thus, the intersubunit site 3 emerges
as a putative unique binding site for the interaction of
1-BuOH and halothane with K-Shaw2 (Fig. 7). In this site,
the residue side chains in close proximity to the anesthetic
FIGURE 6 In silico docking of halothane to
K-Shaw2 (closed and open conformations) and
Kv1.2 (closed). Shown are lateral (A) and bottom
(B) views of K-Shaw2 in the closed conformation
(S4-S5 linker through the S6 segment). In silico
docking solutions returned eight possible sites
(sites 1–8; Supporting Material). Colored blobs
represent the computed density isosurface of the
ligand on a given receptor site. (C) Calculated
ligand-binding constants (Bi) for sites 1–8 (Sup-
porting Material). (D–F) Idem for the open confor-
mation of K-Shaw2. (G–I) Idem for the closed
conformation of Kv1.2. Bi ¼ 0 indicates that the
ligand has no affinity for the site.
Anesthetic Sites in a Kþ Channel 1619molecule (Table S5) do not correspond to those of high-im-
pact Ala/Val mutations (Figs. 3 and 4; Table 1). The residue
side chains lining site 3 are L315, L318, I319, and F322 in
the S4-S5 linker from the same subunit, whereas L331,
L332, F335 (in S5), and L407 (in S6) are from a neighboring
subunit. These results suggest that Ala/Val mutations in the
regions of interest may not primarily perturb physical
contacts, and highlight the importance of allosteric interac-
tions involving distinct binding and effector sites in the
mechanism that governs the inhibition of K-Shaw2 by
general anesthetics.TABLE 1 Residues% 4.7 A˚ from the ligand at selected sites
Ligand Site S4-S5 linker S5 S6DISCUSSION
To gain insights into the structural basis of general anes-
thetic action on voltage-gated ion channels, we investigated
K-Shaw2, a unique Kv channel that displays inhibition by
n-alcohols and inhaled anesthetics at clinically relevant
concentrations. Our results support the notion of distinct
but contiguous binding and effector sites implicating
components of the channel’s activation gate. The following
discussion highlights the mechanistic implications of the
our results.3 L315 L318
I319 F322
L331 L332
F335
L407
1-Butanol 6 K316 Q320 Y419 T423
8 V409
2 I317 K327 E328 V411 S414 N415
F416 Y420
Halothane 3 L315 L318
I319 F322
L332 F335 L407
5 L332 V333
L336
V402 L403 T404
L407 P408Cooperative modulation of K-Shaw2 by general
anesthetics
Although the inhibition of wild-type K-Shaw2 by n-alcohols
and halothane is weakly cooperative (nH ¼ 1.2–1.6), the
investigatedmutations not only change theK0.5, they system-
atically change nH (Figs. 2–4; Table S2 and Table S3).
Compared with the wild-type, some mutations lower thenH (0.8) and others increase it (nH ¼ 2–4). In some extreme
cases, such as A326V/A417V and A326V/Y419A, an
apparent association between large nH and largeK0.5 suggests
that highermultiple-site occupancy is needed to achieve inhi-
bitionwhen the apparent affinity of the anesthetic sites is very
low. Cooperativity is expected because Kv channels are
tetrameric and therefore have four possible binding inter-
faces that may interact allosterically. The general systematic
correlations between DDG and nH for both 1-BuOH and
halothane (Figs. 3 C and 4 C) suggest that the mutations
may mainly influence effector sites allosterically coupled
to binding sites. Indicating a reciprocal communication
between anesthetic binding and effector sites, the roles
of these effector sites are then twofold: 1), regulate coopera-
tive multisite occupancies; and 2), engage in intra- and inter-
subunit interactions, which are discouraged or enhanced
upon anesthetic binding to modulate gating. The latter
emerges from the significant nonadditive energetic impact
of several double mutations on the inhibitions of K-Shaw2Biophysical Journal 101(7) 1613–1622
FIGURE 7 Average equilibrium conformation
of the K-Shaw2 closed-state structure bound to
1-BuOH and halothane. (A) Side view of K-Shaw2
with backbones colored in navy blue and off-
white. The density blob (yellow) depicts 1-BuOH
bound to site 3. Residue side chains < 4.7 A˚ from
1-BuOH are represented as green sticks (Table 1).
(B) Close-up view of 1-BuOH in site 3. (C) Close-
up view of 1-BuOH effector sites. Red-colored
side chains indicate that Ala/Val mutations had an
unfavorable energetic impact on the inhibition of
K-Shaw2 by 1-BuOH, and blue-colored side chains
indicate a favorable energetic impact. (D) As in
panel B, but displaying halothane in site 3. (E) As
in panel C, but displaying the effects of mutations
on the inhibition by halothane.
1620 Barber et al.by 1-BuOH and halothane. Independently of the channel’s
oligomeric structure, whether this cooperativity may instead
or additionally result from local rearrangements within the
binding cavity remains to be investigated.Colocalization of gating and general anesthetic
sites in K-Shaw2
The canonical mechanism of voltage-dependent activa-
tion gating in cation channels involves electromechanical
coupling between the movement of voltage sensors and
opening of the S6 bundle crossing that constitutes the
main internal activation gate (16–18,33–36). This coupling
is made possible by the S4-S5 linkers, which interact with
the distal intracellular portion of the S6 segments. Accord-
ingly, it is not surprising that gating alterations may result
from mutations in these regions (Fig. S1 and Table S4).
Also, because general anesthetic action on K-Shaw2 is
gating-state-dependent, perturbations (mutations or voltage)
that destabilize the resting/closed states or strongly favor the
open state would be predicted to have a negative impact on
anesthetic action. We found several clear examples of these
predictions (see Results). Interestingly, however, we also
found several instances in which the mutations had a signif-
icant energetic impact on the inhibition by 1-BuOH and
halothane, but had no major effect on voltage-dependent
gating, such as S325A, S414A, Y420A, and A326V/
Y420A (Table S4). The lack of a systematic general corre-
lation between gating effects and the energetic impact on
anesthetic action indicates that a subset of mutations mainly
disrupt anesthetic effector sites. Our results are thus consis-
tent with the coexistence of gating and anesthetic sites in the
S4-S5 linker and the post-PVP S6 segment of K-Shaw2.
The constitutively open K-Shaw2 P410D mutant yielded
one of the most striking results because it is essentially
insensitive to the tested general anesthetics. We propose
that the conformational change that underlies the opening
of the activation gate dramatically rearranges the structure
of the anesthetic binding sites. This idea is supported by
in silico docking experiments demonstrating that theBiophysical Journal 101(7) 1613–1622preferred site (site 3) has very low affinity in the open state
of K-Shaw2 and is therefore virtually absent (Fig. 6 and
Fig. S7). These interpretations are in line with the notion
of a relatively large conformational change underlying the
opening of the internal activation gate upon voltage-depen-
dent activation in Kv channels (37).Structural correlates of general anesthetic action
in K-Shaw2
The K-Shaw2 S4-S5 linker presents major primary-
sequence variations compared with the homologous region
in related Kv channels. For instance, residues I319, F322,
and A326 are not found in general anesthetic-resistant
Kv channels. Interestingly, the side chains of hydrophobic
residues I319 and F322 are modeled in close proximity
(%4.6 A˚) to halothane in site 3 (Fig. 7), the preferred
consensus site of anesthetic action in K-Shaw2. L315,
L318 (S4-S5 linker), L332, F335 (S5), and L407 (S6) are
also in close proximity to halothane but are better conserved
across Kv channel subfamilies. Given the predicted archi-
tecture of site 3, how can we reconcile the thermodynamic
map of individual mutations with the predicted locations
of the implicated side chains? Generally, the DDG of indi-
vidual Ala/Val mutations in S4-S5 and S6 is small or modest
(Figs. 3 and 4). The recently published crystal structures of a
ligand-gated ion channel bound to propofol or desflurane
provides possible answers (6). The authors suggested that
the mobility of propofol in its pocket may explain discrep-
ancies between side-chain positions and the effects of the
respective mutations on the inhibitory action of the anes-
thetics. A previous study also showed this fluidity in the
hydrophobic general anesthetic binding site of apoferritin
(5). This explanation is plausible because typically, binding
of general anesthetics to proteins is weakly constrained
by specific structural features (1,4). In response to modest
mutational perturbations, a general anesthetic may adopt
an alternative low-energy state in the protein pocket. There-
fore, a single Ala/Val mutation may not be disruptive
enough to affect the binding of halothane and 1-BuOH to
Anesthetic Sites in a Kþ Channel 1621K-Shaw2, as the ligand may move to establish new non-
specific contacts with the protein backbone and/or mem-
brane phospholipids to facilitate stable binding (38). In
future work, investigators should validate this model by
investigating the disruption of anesthetic effects by system-
atic perturbations of residues in binding site 3.
Residues in the effector sites that determine the stability
of the closed state through more-specific interactions are,
however, more sensitive to mutations. Residues in this cate-
gory are Q320, T321, S325, A326, E328, L329, A417,
M418, Y419, and Y420. The correlation between the nH
and the energetic impact of all mutations and the relatively
large coupling energies between a subset of residue pairs
indicate that K-Shaw2 effector residues influence binding
cooperativity and dictate anesthetic action more strongly
than those predicted to be in closer proximity to the anes-
thetic molecule in the hydrophobic cavity. The double
mutant A326V/A417V is an interesting example of stringent
interactions controlling gating at effector sites, because
although the substitutions are mild, the sensitivity of the
double mutant to the anesthetics is nearly eliminated.Relation to other studies
Several earlier studies focused on the interactions between
general anesthetics and archetypical eukaryotic Kv channels
expressed heterologously, and demonstrated interesting
modulations occurring at relatively high doses (38–41).
We found that ShakerB and Kv1.2 channels are inhibited
%10% by relatively high doses of halothane (1–2 mM),
and their 1-BuOH K0.5-values are 50 and 120 mM, respec-
tively (data not shown). Thus, these Kv channels are
considered general-anesthetic-resistant. In a recent study,
Finol-Urdaneta et al. (42) reconstituted the prokaryotic Kv
channel (KvAP) in planar lipid bilayers and investigated
the modulation of this channel by surface-active substances
(including general anesthetics). The authors observed inter-
esting inhibitory modulations and proposed that, depending
on the conformational susceptibility of ion channels, a mech-
anism of general anesthetic action may involve nonspecific
membrane effects (e.g., changes in surface tension and
phospholipid packing). We did not test these possibilities
in our experiments; however, our results do not rule them
out. Given the S4-S5 linker’s interfacial location at the
membrane, it may help transduce lipid bilayer-mediated
effects of general anesthetics. Further work is necessary to
test this hypothesis.
Generally, the K-Shaw2 mechanism of anesthetic action
agrees well with recently reported high-resolution crystallo-
graphic observations directly demonstrating the binding of
propofol and desflurane to a discrete site in a prokaryotic
Hþ-gated ion channel (GLIC) homologous to eukaryotic
Cys-loop receptors (6). Here, the anesthetic cavity involves
an interface between helical segments of the channel protein
in a region that plays a critical role in gating. This cavity canaccommodate either propofol or desflurane, but the binding
determinants are distinct and the anesthetics exhibit signif-
icant mobility when occupying the site. As proposed for
K-Shaw2, general anesthetics also stabilize the closed state
of GLIC and a subset of related ligand-gated ion channels.CONCLUSIONS
We conclude that helical regions of the S4-S5 linker and the
S5 and S6 segments of K-Shaw2 form inter- and intrasubu-
nit interfaces that delineate a putative general anesthetic
binding pocket/cavity. In this cavity, the side chains of
hydrophobic residues surround the anesthetic molecule,
and neighboring side chains in the activation gate are allo-
sterically coupled to general anesthetic partitioning into
the hydrophobic cavity to ultimately modulate the stability
of the closed state. The general structural features of the
modeled cavity (inter- and intrasubunit helical regions and
a hydrophobic interior) are consistent with those found by
crystallographic methods in other proteins exhibiting rele-
vant general anesthetic-binding sites (5,6). We hypothesize
that the regions identified in the K-Shaw2 channels may
also contribute to general anesthetic action in voltage-gated
Naþ, Ca2þ, and nonselective cation channels (19–25).
Gating of these channels is also essentially dependent on
the interaction between the S4-S5 linkers and the S6
segments (16–18,33–36).SUPPORTING MATERIAL
Experimental details about the Ala/Val scanning mutagenesis, heterologous
expression, electrophysiology, MD simulations, and in silico docking, and
five tables and seven figures are available at http://www.biophysj.org/
biophysj/supplemental/S0006-3495(11)00972-6.
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